ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Companies

Nobel laureate demands higher cancer drug royalties from Ono Pharma

2018 winner in medicine plans to renegotiate contract for blockbuster Opdivo

Kyoto University professor Tasuku Honjo, left, speaking about his royalty payments for the revolutionary cancer drug Opdivo.

TOKYO -- A Japanese Nobel laureate is demanding more money for his role in developing the breakthrough cancer treatment Opdivo, saying Wednesday that co-developer Ono Pharmaceutical should pay him a higher percentage of profits than in their 2006 contract.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more